EnteroMedics has raised net proceeds of about $12 million in a public offering. The St. Paul, Minn.-based company will use the money to seek FDA approval for its Maestro RC system, which uses vagal nerve blocking to help treat patients with obesity, as well as to market the product outside the U.S.

Related Summaries